Redcare Pharmacy's Policy Windfall Ignites a Short Squeeze

A 50% rise in prescription co-payments could drive millions to online pharmacies, fueling a short squeeze in Redcare stock despite strong Q1 2026 results.

A potential overhaul of Germany's prescription drug co-payments is sending shockwaves through the online pharmacy sector and triggering a violent market reaction in shares of Redcare Pharmacy. The stock, heavily targeted by short sellers, is experiencing a powerful squeeze as investors scramble to price in a regulatory shift that could funnel millions of cost-sensitive patients toward digital platforms.

The catalyst is a recommendation from a government-appointed expert commission to raise statutory co-payments for prescription medicines by 50%, moving the range from 5-10 euros to 7.50-15 euros per prescription. Health Minister Nina Warken has pledged to advance corresponding legislation swiftly. Analyst Felix Dennl of Bankhaus Metzler argues that higher out-of-pocket costs will drive price-sensitive patients to seek cheaper alternatives, a trend that disproportionately benefits mail-order pharmacies like Redcare.

This political tailwind arrives as the company demonstrates formidable operational strength, particularly in its core prescription business. Preliminary figures for the first quarter of 2026 showed group revenue climbing 18.3% to 848 million euros, surpassing the analyst consensus of 837 million. The growth was powered by a 35% surge in total prescription (Rx) revenue, with sales in Germany alone jumping 55% to 168 million euros. The company now serves 14.2 million active customers.

Redcare's dominant 67% market share in the German online Rx segment provides a formidable moat. This position is further reinforced by a European Court of Justice ruling granting EU-registered online pharmacies pricing freedom for prescription drugs. Notably, competitor Rossmann has confirmed it will not enter the prescription market, alleviating one investor concern even as drugstore chain dm launched its own online pharmacy, "dm-med," in December.

Despite the strong fundamentals and regulatory support, the stock's performance has been dismal year-to-date, down approximately 40-42% from January levels. It remains a notable laggard in the MDAX index, trading near 39 euros, a far cry from its 52-week high of 136.20 euros. This disconnect between business performance and share price had made the equity a prime target for short sellers, whose forced covering is now amplifying the upward move.

Investor attention this week is fixed on the Annual General Meeting on April 15, which is set to approve the most significant leadership overhaul in the company's recent history. Three long-standing supervisory board members are stepping down, with Anja Hendel, Max Müller, and Peter Schmid von Linstow nominated as successors. The meeting will also officially confirm Hendrik Krampe as the new Chief Financial Officer.

Krampe brings eight years of experience as Finance Director for Amazon's European marketplace business, plus a prior stint at eBay. His expertise in scaling online platform economies is viewed as strategically critical for Redcare's next phase of growth. The new leadership team will face its first major test on May 6 with the release of the detailed Q1 2026 report, which will provide clarity on profitability and margins beyond the preliminary revenue figures disclosed on April 8.

While the short-term dynamics are dramatic, analyst sentiment remains constructive on the long-term digital prescription opportunity. Deutsche Bank reaffirms a "Buy" rating with a 99-euro price target, while Jefferies is even more bullish at 150 euros. The upcoming quarters will reveal if Redcare's roaring prescription growth can sustainably offset intensifying competition in the over-the-counter segment and deliver on its confirmed annual targets.